《新股消息》科倫博泰(06990.HK):中長期擬建立國際化臨床開發及商業化能力
科倫博泰(06990.HK)執行董事兼總經理葛均友表示,公司是立足於中國、面向全球的生物科技企業,目標建立研發、臨床、生產、質量控制及商業化的一體化體系,中長期有計劃建立國際商業化及全球化臨床開發能力。
他續指,目前已訂立九項對外許可協議,當中與默克公司(MRK.US)旗下默沙東已達成三次合作,共涉及9項ADC資產的許可及合作協議,另外亦與和鉑醫藥(02142.HK)達成兩項產品的合作。
至於國內拓展方面,他指出除依托母公司科倫藥業(002422.SZ)的網絡及發展經驗外,自身亦正建立商業化團隊,初步重點專注於中國本土市場的三級醫院與醫生,在完善各項後期候選藥物的商業化策略時,會優先考慮在中國有較高需求的乳腺癌、非小細胞肺癌及胃腸癌症等領域進行研發。
科倫博泰預計旗下首款處於NDA階段的創新藥物A167可於今年下半年至明年上半年取得國家藥監局的附條件上市批准,並有計劃於明年下半年或2025年上半年在中國市場推出核心產品SKB264、A166及A140。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.